drugset / Trial / NCT01354587

Evaluation of Efficacy and Tolerability of Hizentra®

NCT01354587

Unknown 50 enrolled University of South Florida
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to measure the changes in the Treatment Satisfaction Questionnaire for Medication in the areas of effectiveness, side effects, and convenience of administration of each medication in Primary Immunodeficiency Disorder (PIDD) subjects transitioning from subcutaneous Vivaglobin® to Hizentra®.

Timeline

Start
2010-10
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Immune Globulin Intravenous (Human) Protein / enzyme biologic Subcutaneous